GeneScience Pharmaceuticals Co., Ltd. Sustainability Profile
GeneScience Pharmaceuticals Co., Ltd., commonly referred to as GeneScience, is a leading biopharmaceutical company headquartered in China (CN). Established in 2002, the company has made significant strides in the biotechnology sector, focusing on the research, development, and production of innovative biopharmaceuticals. With a strong presence in both domestic and international markets, GeneScience excels in areas such as recombinant proteins, monoclonal antibodies, and biosimilars. Their flagship products, including the well-regarded EPO and G-CSF, are distinguished by their high quality and efficacy, setting them apart in a competitive landscape. Recognised for its commitment to advancing healthcare, GeneScience has achieved notable milestones, including numerous regulatory approvals and partnerships that enhance its market position. As a pioneer in the biopharmaceutical industry, GeneScience continues to drive innovation and improve patient outcomes globally.
DitchCarbon Score
How does GeneScience Pharmaceuticals Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GeneScience Pharmaceuticals Co., Ltd.'s score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GeneScience Pharmaceuticals Co., Ltd.'s reported carbon emissions
GeneScience Pharmaceuticals Co., Ltd., headquartered in China (CN), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Changchun High-Tech Industry (Group) Co., Ltd., which may influence its climate-related initiatives and reporting. While there are no documented reduction targets or commitments from GeneScience Pharmaceuticals, the company is part of a broader industry context that increasingly prioritises sustainability and carbon footprint reduction. The lack of specific emissions data suggests that GeneScience Pharmaceuticals may still be developing its climate strategy or reporting framework. As a subsidiary, any potential climate commitments or emissions data may be cascaded from its parent company, Changchun High-Tech Industry (Group) Co., Ltd. However, no specific initiatives or targets have been outlined in the available information. In summary, GeneScience Pharmaceuticals Co., Ltd. is currently in the process of establishing its climate commitments, with no specific emissions data or reduction targets reported at this time.
How Carbon Intensive is GeneScience Pharmaceuticals Co., Ltd.'s Industry?
How Carbon Intensive is GeneScience Pharmaceuticals Co., Ltd.'s Location?
GeneScience Pharmaceuticals Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GeneScience Pharmaceuticals Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.